Wordt geladen...
Second-line treatment options in hepatocellular carcinoma
For many years, sorafenib has been the only approved systemic treatment for advanced hepatocellular carcinoma (HCC). For over a decade, randomized controlled trials exploring the efficacy of new drugs both in first- and second-line treatment have failed to prove any survival benefit. However, in the...
Bewaard in:
| Gepubliceerd in: | Drugs Context |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioExcel Publishing Ltd
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6469745/ https://ncbi.nlm.nih.gov/pubmed/31024634 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212577 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|